Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Merck & Co (NY:MRK)

84.12 +0.91 (+1.09%)
Official Closing Price Updated: 7:00 PM EDT, Aug 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
24 25 Next >
Merck Provides New Results for VERQUVO® (vericiguat) in Patients with Chronic Heart Failure and Reduced Ejection Fraction
From Merck & Co., Inc.
Via Business Wire
Merck to Participate in the 2025 Wells Fargo Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
HERTHENA-Breast04 Phase 3 Trial of Patritumab Deruxtecan Initiated in Patients with Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer Previously Treated with Endocrine Therapy
From Merck & Co., Inc.
Via Business Wire
Merck Demonstrates Ongoing Commitment to Advancing Cardiovascular Disease Management and Patient Care with New Data at the European Society of Cardiology Congress 2025
From Merck & Co., Inc.
Via Business Wire
Vets and Pet-Owners See Gaps in Flea and Tick Prevention, Highlighting Need for Year-Round Care, New Merck Animal Health Global Survey Finds
From Merck & Co., Inc.
Via Business Wire
Ifinatamab Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Pretreated Extensive-Stage Small Cell Lung Cancer
From Daiichi Sankyo
Via Business Wire
KEYTRUDA® (pembrolizumab) plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free and Overall Survival and Pathologic Complete Response Rate for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery
From Merck & Co., Inc.
Via Business Wire
Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas
Via Investor Brand Network
Topics Government
Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas
EQNX::TICKER_START (NASDAQ:SNGX),(NYSE:PFE),(NYSE:MRK),(NYSE:BMY),(NASDAQ:INSM) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Government
Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2025 Financial Results
From Merck & Co., Inc.
Via Business Wire
Merck Announces Fourth-Quarter 2025 Dividend
From Merck & Co., Inc.
Via Business Wire
MERCK ALERT: Bragar Eagel & Squire, P.C. is Investigating Merck & Co., Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Merck to Initiate Phase 3 Trials for Investigational Once-Monthly HIV Prevention Pill
From Merck & Co., Inc.
Via Business Wire
FDA Approves BRAVECTO® QUANTUM (Fluralaner for Extended-Release Injectable Suspension) from Merck Animal Health
From Merck & Co., Inc.
Via Business Wire
U.S. FDA Accepts New Drug Application for Merck’s Doravirine/Islatravir, an Investigational, Once-Daily, Oral, Two-Drug Regimen for Treatment of Adults with Virologically Suppressed HIV-1 Infection
From Merck Sharp & Dohme
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verona Pharma plc (Nasdaq - VRNA), Olo Inc. (NYSE - OLO), Guaranty Bancshares, Inc. (NYSE - GNTY), MRC Global Inc. (NYSE - MRC)
From Brodsky & Smith LLC
Via GlobeNewswire
Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next Decade
From Merck & Co., Inc.
Via Business Wire
Merck to Present New Data Highlighting Research Advancements Across its HIV Prevention and Treatment Pipeline at IAS 2025
From Merck & Co., Inc.
Via Business Wire
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs
Via Investor Brand Network
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs
EQNX::TICKER_START (NYSE:CLDI),(NASDAQ:REGN),(NASDAQ:VRTX),(OTCQX:RHHBY),(NYSE:MRK) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
FDA Grants Priority Review for WINREVAIR™ (sotatercept-csrk) to Update Label Based on Results From ZENITH Trial
From Merck & Co., Inc.
Via Business Wire
Merck to Hold Second-Quarter 2025 Sales and Earnings Conference Call July 29
From Merck & Co., Inc.
Via Business Wire
ACIP Recommends Use of Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Younger than 8 Months of Age Born During or Entering Their First RSV Season
From Merck & Co., Inc.
Via Business Wire
Merck to Hold Investor Event to Highlight Advancing Research Pipeline for HIV Treatment and Prevention
From Merck & Co., Inc.
Via Business Wire
Merck Announces Phase 3 HYPERION Study of WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Recently Diagnosed Adults with Pulmonary Arterial Hypertension (PAH)
From Merck & Co., Inc.
Via Business Wire
IDeate-Prostate01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Pretreated Metastatic Castration-Resistant Prostate Cancer
From Merck & Co., Inc.
Via Business Wire
FDA Approves KEYTRUDA® (pembrolizumab) for PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy With or Without Cisplatin Then as a Single Agent
From Merck & Co., Inc.
Via Business Wire
Merck Animal Health Receives EU CVMP Positive Opinion for NUMELVI™ (atinvicitinib) Tablets for Dogs
From Merck & Co., Inc.
Via Business Wire
Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate
From Merck & Co., Inc.
Via Business Wire
U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season
From Merck & Co., Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
24 25 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.